Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Moderna, COVID-19 and northwestern university
Moderna appropriated Northwestern research for COVID vaccine, lawsuit alleges
The Evanston college claims Moderna could not have developed the vaccine as quickly as it did in 2020 without its own researchers' technological breakthroughs.
Northwestern sues Moderna for patent infringement over COVID-19 vaccines
Moderna was hit with a new patent lawsuit on Wednesday in Delaware federal court from Northwestern University, which accused the company of misusing the school's innovations to develop its blockbuster COVID-19 vaccine Spikevax.
Moderna Hit With Another Lawsuit Related To Key COVID-19 Vaccine Technology
Northwestern University has filed a lawsuit against Moderna, alleging the company used its patented lipid nanoparticle technology without permission in the development of its COVID-19 vaccines.
GSK sues Moderna over mRNA vaccine technology
GlaxoSmithKline is suing Moderna for allegedly using technology patented by GSK in its COVID-19 vaccine. Why it matters: It's the latest in a series of legal fights over who owns the intellectual property behind mRNA technology and whether some companies are entitled to royalties on future sales.
Northwestern University Sues Moderna Over Spikevax Vaccine
Northwestern University sued vaccine maker Moderna, Inc. on Wednesday, October 16, in the U.S. District Court for the District of Delaware, alleging infringement of three patents the school says cover technology key to the delivery method for Moderna’s groundbreaking messenger-RNA (mRNA) COVID-19 vaccine.
Northwestern sues Moderna for alleged patent infringement in COVID shots
Moderna is facing allegations that it misused innovations from researchers at Northwestern University to develop its mRNA COVID-19 vaccines, which became widely available to the public in 2021 to combat the pandemic.
British drugmaker sues Moderna for patent infringement related to mRNA vaccines
A British drugmaker, GlaxoSmithKline (GSK), has sued American pharmaceutical company Moderna claiming it violated patent rights in its mRNA technology used to develop its COVID-19 and RSV vaccines.
Opinion
1d
Opinion
Commentary: Your vaccine list should include COVID-19 update
As the COVID virus continues to evolve, experts in respiratory diseases recommend that everyone ages 6 months and older ...
10h
on MSN
As new COVID-19 strains emerge, how do vaccine manufacturers keep up with mutations of the virus?
New COVID-19 strains are emerging and with it the need for updated vaccines to protect people from the virus. So how do ...
4d
on MSN
Here’s What You Need to Know About Getting the New 2024 COVID Vaccine
The new COVID vaccine is here, but does it bring any new side effects or reactions? Here's what the COVID booster 2024 side ...
13d
Low RSV and COVID vaccine usage is in line with investor expectations, but concerning: Jefferies
Low uptake in the RSV and COVID vaccine markets is not surprising, an analyst says, and could mean weak earnings for ...
3d
on MSN
Novavax’s stock slides 19% after FDA puts clinical hold on COVID and flu vaccine candidates
Novavax Inc.’s stock tumbled 16% early Wednesday after the company said the FDA has placed a clinical hold on its ...
Prevention
13d
Which COVID Vaccine Is Better? Infectious Disease Doctors Explain
The new
COVID
-19
vaccine
rolled out across the country last month, giving people access to the most recent versions of the
Moderna
, Pfizer, and Novavax shots. But, given that you have options, ...
The Martha's Vineyard Times
3d
COVID, flu vaccine clinic announced
The Vineyard boards of health are teaming up to bring vaccines back to the community at the end of the month. It’s not the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Northwestern University
Novavax
Pfizer
mRNA
GSK
Feedback